Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Nutriband Inc.
Nutriband Inc. News
Nutriband Inc. Quantitative Score
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Nutriband Inc. Financials
Table Compare
Compare NTRB metrics with: | |||
|---|---|---|---|
Earnings & Growth | NTRB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NTRB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NTRB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NTRB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Nutriband Inc. Income
Nutriband Inc. Balance Sheet
Nutriband Inc. Cash Flow
Nutriband Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Nutriband Inc. Executives
| Name | Role |
|---|---|
| Dr. Alan Smith Ph.D. | Chief Operating Officer & President of 4P Therapeutics |
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board |
| Mr. Gareth Sheridan | Founder, Chief Executive Officer & Director |
| Mr. Gerald Goodman | Chief Financial Officer & Chief Accounting Officer |
| Mr. Michael Myer | President of Pocono Pharmaceutical |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Alan Smith Ph.D. | Chief Operating Officer & President of 4P Therapeutics | 1966 | 159K | |
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board | Male | 1974 | 155K |
| Mr. Gareth Sheridan | Founder, Chief Executive Officer & Director | Male | 1990 | 155K |
| Mr. Gerald Goodman | Chief Financial Officer & Chief Accounting Officer | Male | 1948 | 115K |
| Mr. Michael Myer | President of Pocono Pharmaceutical | Male | 1984 | 40.6K |
Nutriband Inc. Insider Trades
| Date | 20 Mar |
| Name | Goodman Gerald |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 75000 |
| Date | 6 Jun |
| Name | Goodman Gerald |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 87500 |
| Date | 20 Mar |
| Name | MELNIK SERGUEI |
| Role | President and Secretary |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 97500 |
| Date | 20 Mar |
| Name | Sheridan Gareth |
| Role | CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 75000 |
| Date | 16 Aug |
| Name | Goodman Gerald |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 23333 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 20 Mar | Goodman Gerald | Chief Financial Officer | Acquired | A-Award | 75000 |
| 6 Jun | Goodman Gerald | Chief Financial Officer | Acquired | M-Exempt | 87500 |
| 20 Mar | MELNIK SERGUEI | President and Secretary | Acquired | A-Award | 97500 |
| 20 Mar | Sheridan Gareth | CEO | Acquired | A-Award | 75000 |
| 16 Aug | Goodman Gerald | Chief Financial Officer | Acquired | A-Award | 23333 |